Evidence
CAnimal replicated
⚠ NAMING COLLISION — Read First
'Lipo-C' refers to two completely different products in commercial and clinical use: (1) THIS CHAPTER: Compounded lipotropic injection = MIC (Methionine + Inositol + Choline) + L-Carnitine + B vitamins (typically thiamine/B1, dexpanthenol/B5) ± B12. A weight loss clinic injectable. (2) NOT THIS CHAPTER: Liposomal Vitamin C = vitamin C encapsulated in phospholipid liposomes for enhanced oral bioavailability. A completely different product, a separate oral supplement. These products share a name only. They have no overlapping ingredients, mechanisms, or applications. When a practitioner or vendor says 'Lipo-C,' always confirm which product is intended.
What L-Carnitine Adds — and the Dose Problem
The mechanistic addition: where Lipo-B's choline/methionine support hepatic fat mobilization (VLDL particle export), L-Carnitine supports peripheral fatty acid transport into mitochondria (CPT-I/CACT system) for beta-oxidation. The narrative: Lipo-B mobilizes fat from the liver → L-Carnitine shuttles those fatty acids into cells for burning. Coherent. THE DOSE PROBLEM: Injectable L-Carnitine at 50 mg/mL means 50 mg per 1 mL injection, 1-2x weekly = 50-100 mg/week total. Oral therapeutic L-Carnitine doses are 1,500-3,000 mg/DAY = 10,500-21,000 mg/week. The injectable Lipo-C L-Carnitine dose is approximately 100-200x below validated oral therapeutic doses. IM injection bioavailability (essentially 100%) does NOT compensate for this 100-200x dose gap.
What B1 and B5 Add
Thiamine (B1) in Lipo-C (typically 15 mg/mL): thiamine pyrophosphate is a cofactor for pyruvate dehydrogenase (glucose → acetyl-CoA) and alpha-ketoglutarate dehydrogenase in the Krebs cycle; essential for carbohydrate metabolism; deficiency causes beriberi (wet: cardiac; dry: neurological) and Wernicke encephalopathy. Common in alcoholism, bariatric surgery patients, severe malnutrition. At 15 mg/mL injectable: well above dietary RDA (1.1-1.2 mg/day). Beneficial for deficient states; unnecessary for adequately nourished individuals. Dexpanthenol (B5, as provitamin in Lipo-C, typically 5 mg/mL): converted to pantothenic acid (B5) → coenzyme A (CoA); CoA essential for fatty acid activation and Krebs cycle entry; B5 deficiency rare (present in essentially all foods). Beneficial for deficient states; marginal addition for adequately nourished individuals.
Lipo-C vs Lipo-B — The Clinical Comparison
The key clinical comparison: clinical evidence does not show meaningful fat loss differences between Lipo-B and Lipo-C when both are dosed weekly at standard concentrations alongside caloric restriction. This is the honest conclusion from available evidence. The additional ingredients in Lipo-C (L-Carnitine, B1, B5) provide broader nutritional coverage but do not appear to produce meaningfully superior weight loss outcomes at standard medspa protocols. Lipo-C may have specific advantages for populations with higher carnitine needs (vegans, CKD, elderly) or thiamine deficiency risk (alcoholism history, bariatric surgery).
Evidence Status
Same as Lipo-B: ZERO RCTs for the Lipo-C combination as a weight loss intervention. Individual components have evidence at the ingredient level. L-Carnitine at therapeutic oral doses (1.5-3g/day) has Grade B evidence for specific indications (neuropathy, PAD, cardiac). At Lipo-C injectable doses (50 mg/injection), the dose-response curve may not reach pharmacologically meaningful levels for these specific indications. The Chapter inherits Lipo-B's Grade E combination evidence and adds the carnitine, B1, and B5 component analysis.